BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 23815697)

  • 1. Microwave endometrial ablation for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Zhu Y; Yang J
    J Obstet Gynaecol Res; 2013 Sep; 39(9):1411-4. PubMed ID: 23815697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indication of hysteroscopy in tamoxifen treated breast cancer patients.
    Taponeco F; Curcio C; Fasciani A; Giuntini A; Artini PG; Fornaciari G; Petraglia F; Genazzani AR
    J Exp Clin Cancer Res; 2002 Mar; 21(1):37-43. PubMed ID: 12071527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of endometrial proliferation in pipelle biopsies in tamoxifen-treated postmenopausal women with breast cancer in Kuwait.
    Al-Azemi M; Labib NS; Motawy MM; Temmim L; Moussa MA; Omu AE
    Med Princ Pract; 2004; 13(1):30-4. PubMed ID: 14657616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients.
    Cheng WF; Lin HH; Torng PL; Huang SC
    Gynecol Oncol; 1997 Aug; 66(2):233-7. PubMed ID: 9264568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [MR Imaging of the pelvis in the diagnosis of the endometrium in breast cancer patients in tamoxifen therapy].
    Hauth E; Libera H; Kimmig R; Forsting M
    Rofo; 2006 Mar; 178(3):316-23. PubMed ID: 16508840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer.
    Deligdisch L; Kalir T; Cohen CJ; de Latour M; Le Bouedec G; Penault-Llorca F
    Gynecol Oncol; 2000 Aug; 78(2):181-6. PubMed ID: 10926800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Uterine abnormalities in non menopausal women who received tamoxifen for breast cancer adjuvant therapy].
    d'Arailh AS; Michy T; Pioud R; Dravet F; Classe JM
    Gynecol Obstet Fertil; 2007 Dec; 35(12):1215-9. PubMed ID: 18035581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Endometrial ablation versus hysterectomy in women treated with tamoxifen].
    Capuano I; Caporale A; Vagnetti P; Di Domenico A; Felicetti M; Torella M; Borrelli AL
    Minerva Ginecol; 2007 Oct; 59(5):499-504. PubMed ID: 17912176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endometrial tubal metaplasia in a young puerperal woman after breast cancer.
    Di Benedetto L; Giovanale V; Caserta D
    Int J Clin Exp Pathol; 2015; 8(6):7610-3. PubMed ID: 26261678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women.
    Marttunen MB; Cacciatore B; Hietanen P; Pyrhönen S; Tiitinen A; Wahlström T; Ylikorkala O
    Br J Cancer; 2001 Apr; 84(7):897-902. PubMed ID: 11286468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen use and endometrial lesions: hysteroscopic, histological, and immunohistochemical findings in postmenopausal women with breast cancer.
    Dibi RP; Zettler CG; Pessini SA; Ayub AV; de Almeida SB; da Silveira GP
    Menopause; 2009; 16(2):293-300. PubMed ID: 19034048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Risk of endometrial hyperplasia and carcinoma in breast cancer patients receiving adjuvant tamoxifen].
    Semiglazov VF; Maksimov SIa; Bulgatova EA; Meshkova IE; Chepik OF; Berstein LM
    Vopr Onkol; 2003; 49(2):198-204. PubMed ID: 12785205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term "protective" effect of aromatase inhibitors on the endometrium of postmenopausal breast cancer patients.
    Markovitch O; Tepper R; Fishman A; Aviram R; Cohen I
    Breast Cancer Res Treat; 2009 Jan; 113(2):321-6. PubMed ID: 18297393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different coexisting endometrial histological features in asymptomatic postmenopausal breast cancer patients treated with tamoxifen.
    Cohen I; Altaras MM; Shapira J; Tepper R; Cordoba M; Figer A; Zalel Y; Dror Y; Beyth Y
    Gynecol Obstet Invest; 1997; 43(1):60-3. PubMed ID: 9015703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.
    Pinkerton JV; Goldstein SR
    Menopause; 2010; 17(3):642-53. PubMed ID: 20107426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen.
    Lee M; Piao J; Jeon MJ
    Yonsei Med J; 2020 Apr; 61(4):317-322. PubMed ID: 32233174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen and endometrial pathologies: a prospective study.
    Seoud M; Shamseddine A; Khalil A; Salem Z; Saghir N; Bikhazi K; Bitar N; Azar G; Kaspar H
    Gynecol Oncol; 1999 Oct; 75(1):15-9. PubMed ID: 10502419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hysteroscopically targeted biopsies compared with blind samplings in endometrial assessment of menopausal women taking tamoxifen for breast cancer.
    Garuti G; Cellani F; Colonnelli M; Garzia D; Gonfiantini C; Luerti M
    J Am Assoc Gynecol Laparosc; 2004 Feb; 11(1):62-7. PubMed ID: 15104834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endometrial pathologies associated with postmenopausal tamoxifen treatment.
    Cohen I
    Gynecol Oncol; 2004 Aug; 94(2):256-66. PubMed ID: 15297160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen.
    Kesim MD; Aydin Y; Atis A; Mandiraci G
    Climacteric; 2008 Jun; 11(3):252-7. PubMed ID: 18568790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.